Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06375915

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE)

Single Arm, Multicenter Phase II Study Investigating the Efficacy and Safety of a Novel Therapeutic Scheme in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization in Combination With CisGem and Durvalumab (MEDI4736)

Sponsor: A.O. Ospedale Papa Giovanni XXIII

Conditions Intrahepatic Cholangiocarcinoma

Interventions Cisplatin Durvalumab Gemcitabine radioembolization with Y-90

Updated 5 times since 2024 Last updated: May 23, 2024 Started: May 1, 2024 Primary completion: Jan 31, 2026 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Intrahepatic Cholangiocarcinoma and is currently actively recruiting participants. A.O. Ospedale Papa Giovanni XXIII leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

A.O. Ospedale Papa Giovanni XXIII
AOU Pisana, Pisa, Italy
Cardarelli Hospital
Francesco De Cobelli

Data source: IRCCS San Raffaele

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy